BioSpace.com News

PTC Therapeutics, Inc. Files for a $85 Million IPO Following Failed IPO Attempt in 2006

Fri, 17 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering

SOUTH PLAINFIELD, N.J., May 16, 2013 /PRNewswire...

Esperion Therapeutics, Inc. Files for $70 Million IPO

Thu, 16 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

A Plymouth Township-based biotech company founded by a scientist who co-discovered the best-selling pharameutical drug ever has filed documents to go public. Esperion Therapeutics, formed five years ago by Michigan...

Regado Biosciences Files for a $75 Million IPO

Tue, 30 Apr 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BASKING RIDGE, N.J., April 29, 2013 /PRNewswire/ -- Regado Biosciences, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities...

Biotech Receptos Files for a $86 Million IPO

Fri, 05 Apr 2013 12:00:00 AM GMT

Receptos, a biotech with a Phase 3 drug candidate for relapsing multiple sclerosis, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The San Diego, CA-based company, which was founded in 2008 and has yet to generate any revenue from drug sales, plans to list on the NASDAQ under the symbol RCPT.

Omthera Pharmaceuticals, Inc. Files for a $75 Million IPO

Mon, 11 Mar 2013 12:00:00 AM GMT

Omthera Pharmaceuticals has joined the wave of companies wanting to come public. Omthera is a clinical stage biotech and will trade under the ticker OMTH on Nasdaq after its initial public offering. The underwriting group consists of BofA/Merrill Lynch, Barclays, Leerink Swann, Stifel and Piper Jaffray. The company is an emerging specialty pharmaceutical company focused on the development and commercialization...

Ambit Biosciences Refiles for a $58 Million IPO

Thu, 21 Feb 2013 12:00:00 AM GMT

SAN DIEGO, Feb. 20, 2013 /PRNewswire/ -- Ambit Biosciences Corporation today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for an initial public offering of its common stock on the NASDAQ stock market. All shares of common stock to be sold in the offering will be offered by Ambit. The number...

Quintiles, Inc. Files for IPO of Up to $600 Million

Tue, 19 Feb 2013 12:00:00 AM GMT

Quintiles Transnational Holdings Inc, the largest provider of testing services to drugmakers, filed with U.S. regulators on Friday to raise up to $600 million in an initial public offering of common stock. The company, backed by private equity investors that include Bain Capital LLC and TPG Capital LP, did not reveal how many shares it planned to sell or their expected price. Quintiles, which runs...

Sophiris Bio Inc. Files for a $75 Million IPO

Tue, 19 Feb 2013 12:00:00 AM GMT

SAND DIEGO and VANCOUVER, Feb. 18, 2013 - Sophiris Bio Inc. (Sophiris, TSX: SHS) ("Sophiris" or the "Company"), a biopharmaceutical company developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate), previously announced on February 15, 2013 that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial...

TetraPhase Pharmaceuticals Files for a $86 Million IPO

Wed, 13 Feb 2013 12:00:00 AM GMT

Antibiotics developer Tetraphase Pharmaceuticals Inc. has filed regulatory documents announcing its intentions to launch an initial public offering. Tetraphase has applied to list its common stock on the Nasdaq stock exchange under the symbol TTPH. The Cambridge, Mass.-based, privately-held biotechnology company launched in 2006, and has until now received all of its revenue from three government...

Harvard Bioscience Inc. Announces Filing of IPO Registration Statement for

Wed, 12 Dec 2012 12:00:00 AM GMT

HOLLISTON, Mass., Dec. 11, 2012 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of tools to advance life science research and regenerative medicine, today announced that its wholly-owned subsidiary, Harvard Apparatus Regenerative Technology, Inc., filed a registration statement with the SEC for an initial public offering, or...

KaloBios Pharmaceuticals, Inc. Files for IPO

Fri, 05 Oct 2012 12:00:00 AM GMT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- KaloBios Pharmaceuticals, Inc. today announced that it filed a Registration Statement with the Securities and Exchange Commission for a Proposed Initial Public Offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

Leerink Swann LLC is serving as sole book-running manager...

Paratek Pharmaceuticals, Inc. Files for a $92 Million IPO

Fri, 28 Sep 2012 12:00:00 AM GMT

BOSTON, Sept. 27, 2012 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Paratek. The number...

Intercept Pharmaceuticals Files for $75 Million IPO

Wed, 05 Sep 2012 12:00:00 AM GMT

NEW YORK, Sept. 4, 2012 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed...

Regulus Therapeutics, Inc. Files for Up to $58 Million IPO

Mon, 20 Aug 2012 12:00:00 AM GMT

LA JOLLA, Calif., Aug. 20, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company founded by Alnylam Pharmaceuticals (NASDAQ: ALNY) and Isis Pharmaceuticals (NASDAQ: ISIS), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public...

Pfizer Inc.'s Animal Health Unit Files for $100 Million IPO

Mon, 13 Aug 2012 12:00:00 AM GMT

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE) today announced that its subsidiary, Zoetis Inc. (zo-EH-tis), filed a registration statement with the U.S. Securities and Exchange Commission for a potential initial public offering (IPO) of Class A common stock. The offering is expected to represent an ownership stake of up to 20 percent. Prior to completion of the offering, which is targeted for the...

Audeo Oncology Files for $60 Million IPO

Mon, 09 Jul 2012 12:00:00 AM GMT

SAN FRANCISCO, CA--(Marketwire - July 09, 2012) - Audeo Oncology, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be sold and the price range for the proposed offering have not yet been determined.

Leerink Swann LLC and...

GlobeImmune, Inc. Files Paperwork for $69 Million IPO

Tue, 03 Jul 2012 12:00:00 AM GMT

LOUISVILLE, CO--(Marketwire - July 02, 2012) - GlobeImmune, Inc., today announced that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of...

Kythera Biopharmaceuticals Files for $86.3 Milion IPO

Thu, 17 May 2012 12:00:00 AM GMT

LOS ANGELES--(BUSINESS WIRE)-- KYTHERA Biopharmaceuticals, Inc. (KYTHERA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that it has publicly filed its registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed...

OncoMed Pharmaceuticals, Inc. Files for $115 Million IPO

Mon, 14 May 2012 12:00:00 AM GMT

San Francisco Business Times by Ron Leuty, Reporter

OncoMed Pharmaceuticals Inc. is seeking $115 million in an initial public stock offering, the company said Friday.

The Redwood City-based cancer drug developer, one of the most successful Bay Area biotech companies at raising venture capital over the past five years, said it will use proceeds of the IPO to advance its lead drug...

Hyperion Therapeutics Files for $58 Million US IPO

Fri, 13 Apr 2012 12:00:00 AM GMT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Hyperion Therapeutics, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

Leerink Swann LLC and Cowen and Company, LLC are serving...

Stemline Therapeutics, Inc. Files for $50 Million US IPO

Tue, 03 Apr 2012 12:00:00 AM GMT

NEW YORK, April 3, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock...

Tesaro, Inc. Seeks $86.2 Million IPO

Tue, 27 Mar 2012 12:00:00 AM GMT

TESARO Inc., a Waltham, Mass.-based biotech licensing and developing cancer therapies and oncology supportive care products, has filed for an initial public offering of stock with the aim of raising $86.2 million. The firm last June raised $101 million in a Series B round led by West Coast venture firm Kleiner Perkins Caulfield & Byers, and other backers include New Enterprise Associates, which took...

Durata Therapeutics, Inc. Files for $86 Million US IPO

Fri, 23 Mar 2012 12:00:00 AM GMT

MORRISTOWN, N.J.--(BUSINESS WIRE)-- Durata Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock.

BofA Merrill Lynch and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the proposed offering, with RBC Capital...

Newsummit Biopharma Files for $80 Million NYSE IPO

Mon, 27 Feb 2012 12:00:00 AM GMT

February 25, 2012 -- Newsummit Biopharma Holdings, a Shanghai-based CRO offering pre-clinical drug development services, filed to raise up to $80 million in a New York Stock Exchange IPO. The company has offices in five technology parks around China. Newsummit aims to be a one-stop solution for bringing a drug candidate or medical device through an IND (or NDA) filing, after the initial work on the...

Radius Files IPO, Aims for $86 Million

Tue, 07 Feb 2012 12:00:00 AM GMT

CAMBRIDGE, MA, Feb 07, 2012 (MARKETWIRE via COMTEX) -- Radius Health, Inc., a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, today announced that it has filed a registration statement with the Securities and Exchange Commission relating to a proposed public offering of its common stock. The number of shares to...

Rib-X Pharmaceuticals, Inc. Files for $80 Million IPO

Mon, 28 Nov 2011 12:00:00 AM GMT

NEW HAVEN, CT, November 28, 2011 Rib-X Pharmaceuticals, Inc. announced today that the Company has filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.Deutsche Bank Securities will act as the sole book...

BioAmber Inc. Files Registration Statement for Proposed Initial Public Offering

Mon, 14 Nov 2011 12:00:00 AM GMT

MINNEAPOLIS, MN, Nov. 14, 2011 /PRNewswire/ - BioAmber Inc. has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be offered in the proposed offering and the price range for the offering...

Verastem, Inc. Braves the Public Market, Files for $50 Million IPO

Thu, 03 Nov 2011 12:00:00 AM GMT

CAMBRIDGE, Mass., Nov 03, 2011 (BUSINESS WIRE) -- Verastem, Inc. a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares...

Cempra Holdings, LLC. Files Registration Statement for $86 Million Proposed Initial Public Offering

Thu, 13 Oct 2011 12:00:00 AM GMT

CHAPEL HILL, N.C., Oct. 12, 2011 /PRNewswire/ -- Cempra Holdings, LLC, the parent holding company of Cempra Pharmaceuticals, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to its proposed initial public offering.

Stifel Nicolaus Weisel, Leerink Swann LLC and Cowen...

Argos Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering

Fri, 29 Jul 2011 12:00:00 AM GMT

DURHAM, N.C., July 29, 2011 /PRNewswire/ -- Argos Therapeutics, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold...

Cathay Industrial Biotech Files $200 Million IPO

Wed, 20 Jul 2011 12:00:00 AM GMT

Cathay Industrial Biotech Ltd. (Nasdaq: CBIO) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of it's American Depositary Shares, or ADSs. The proposed maximum offering price is $200 million. Cathay filed to list on the New York Stock Exchange under the ticker "CBIO." The offering is being made through Morgan Stanley, Deutsche Bank, and Jefferies...

Coronado Biosciences Files to Become a Public Reporting Company

Mon, 18 Jul 2011 12:00:00 AM GMT

Coronado Biosciences Files to Become a Public Reporting Company

PR Newswire

NEW YORK, July 18, 2011

NEW YORK, July 18, 2011 /PRNewswire/ -- Coronado Biosciences, Inc. (the "Company"), a biopharmaceutical...

Merrimack Pharmaceuticals Inc. Files $172.5 Million IPO

Mon, 11 Jul 2011 12:00:00 AM GMT

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering amount is $172.5 million. Merrimack plans to list on the Nasdaq Global Market under the ticker "MACK."The offering is being made through J.P. Morgan, BofA Merrill Lynch, Cowen and Company, and Oppenheimer...

Myriant Technologies LLC Files for $125 Million IPO

Wed, 01 Jun 2011 12:00:00 AM GMT

Myriant Technologies, a Quincy, MA-based developer of biochemicals, revealed its intention to raise $125 million in an initial public offering, according to documents filed with the SEC. The company plans to put the proceeds toward completing a plant in Louisiana, as well as working capital, research and development, and general corporate purposes. It reported a $16 million net loss on $14 million...

Genetics Instrument Maker Fluidigm Corporation Refiles for $86 million IPO

Mon, 06 Dec 2010 12:00:00 AM GMT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of Fluidigm's common stock. Fluidigm develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or...

Biotech Clarus Therapeutics Files for $86 Million IPO

Tue, 23 Nov 2010 12:00:00 AM GMT

DOW JONES NEWSWIRES -- Clarus Therapeutics Inc. has filed plans to sell up to an estimated $86.3 million in shares in an initial public offering. The pharmaceutical company has applied for its shares to be traded on the Nasdaq Global Market under the symbol CLRS. Clarus, which is developing an oral testosterone replacement therapy called OriTex, plans to use proceeds from the IPO to pay for a Phase...

Beijing Pharma to IPO in Hong Kong

Tue, 23 Nov 2010 12:00:00 AM GMT

November 23, 2010 -- Beijing Pharmaceutical, a subsidiary of China Resources Medications Group, plans to list on the Hong Kong Stock Exchange, one more piece of evidence that Hong Kong is the exchange of choice for large China pharma IPOs. As yet, the size of the offering is not known. However, Beijing Pharmas revenues are expected to hit 16 billion RMB ($2.4 billion) in 2010, up from 10 billion ...

Biotech AcelRx Pharmaceuticals Files For $86 Million IPO

Mon, 15 Nov 2010 12:00:00 AM GMT

REDWOOD CITY, Calif., Nov. 12, 2010 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock...

Sihuan Pharmaceutical Sets $700M IPO

Mon, 04 Oct 2010 12:00:00 AM GMT

Reuters -- Sihuan Pharmaceutical Holdings Group Ltd, China's largest cardio-cerebral vascular drugmaker, plans to raise $600-700 million from a Hong Kong initial public offering this month, sources familiar with the matter told Reuters on Monday, joining a flurry of stock offerings in the city in recent months.

Quark Pharmaceuticals Inc. Seeks Up to $20M IPO

Mon, 27 Sep 2010 12:00:00 AM GMT

San Francisco Business Times -- Quark Pharmaceuticals Inc., a developer of RNA interference drugs that signed a big deal last month with Novartis AG, wants to raise up to $20 million in the Bay Areas latest biotech IPO.

Anacor Pharmaceuticals, Inc. Files to Sell Up To $86.3 Mln in IPO

Mon, 13 Sep 2010 12:00:00 AM GMT

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (Anacor) today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. All shares of the common stock...

Biopharma Company Endocyte, Inc. Files Plan For $86.3 Mln IPO

Wed, 18 Aug 2010 12:00:00 AM GMT

WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Endocyte, Inc., a biopharmaceutical company developing targeted small-molecule drug conjugates, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering...

Pacific Biosciences Files For $200 Mln IPO

Tue, 17 Aug 2010 12:00:00 AM GMT

Aug 16 (Reuters) - Pacific Biosciences of California Inc filed with U.S. regulators on Monday to raise up to $200 million in an initial public offering of common stock.

Biotech Horizon Biopharm Files To Sell Up To $86.3 Mln In IPO

Wed, 04 Aug 2010 12:00:00 AM GMT

NORTHBROOK, Ill., Aug. 3 /PRNewswire/ -- Horizon Pharma, Inc. announced today that it has filed a registration statement on form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company.

...

Complete Genomics, Inc. Seeks IPO; Hopes To Raise $86 Million

Mon, 02 Aug 2010 12:00:00 AM GMT

Xconomy -- Complete Genomics, the Mountain View, CA-based company with a new model for inexpensive gene sequencing, has filed a prospectus with the Securities and Exchange Commission to go public. The company hopes to raise as much as $86 million through an IPO that would be underwritten by UBS, Baird, Jefferies & Co., and Cowen & Co. Complete Genomics already has a couple of well-known investors...

Trius Therapeutics Set to go Public This Week

Wed, 28 Jul 2010 12:00:00 AM GMT

Bloomberg -- Development-stage biotechnology company Trius Therapeutics Inc. expects to raise up to $84 million this week in an initial public offering.

Trius Therapeutics IPO Plans Back on Track

Thu, 22 Jul 2010 12:00:00 AM GMT

Xconomy -- San Diegos Trius Therapeutics, which was forced to postpone its planned IPO earlier this year to accommodate new FDA guidelines, appears to be back on track. The biotech amended its IPO filing with the Securities and Exchange Commission earlier this week, and the companys stock offering is now on the runway and scheduled for the week of July 26, according to Renaissance Capitals IPO calendar...

Epocrates Inc. Files for $75 Million IPO

Mon, 19 Jul 2010 12:00:00 AM GMT

SAN MATEO, Calif., Jul 16, 2010 (BUSINESS WIRE) -- Epocrates, Inc., a leading provider of mobile drug reference tools and interactive services to healthcare professionals and the healthcare industry, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock.

J.P. Morgan...

Migraine Patch Maker NuPathe Inc. Files for $86.3M IPO

Mon, 17 May 2010 12:00:00 AM GMT

Businessweek -- Specialty pharmaceutical company NuPathe Inc., which is developing a patch that treats migraines, on Friday filed for an initial public offering valued at up to $86.3 million.

Ikaria Inc. Files for $200 Million IPO

Fri, 14 May 2010 12:00:00 AM GMT

PE Hub -- Ikaria, a Clinton, N.J.-based biopharma company, has filed for a $200 million IPO. It plans to trade on the Nasdaq under ticker symbol IKAR, with Goldman Sachs and Morgan Stanley serving as co-lead underwriters.

Accretive Health Files for $200 Million IPO

Tue, 04 May 2010 12:00:00 AM GMT

Reuters -- Accretive Health Inc filed with U.S. regulators on Tuesday to raise up to $200 million in an initial public offering of common stock.

Alimera Sciences Expects IPO to Raise About $87 Million

Mon, 19 Apr 2010 12:00:00 AM GMT

AP -- Alimera Sciences Inc., a biopharmaceutical company that specializes in prescription eye drugs, plans an initial public offering of its stock this week. Alimera is conducting two late-stage clinical trials for Iluvien, which aims to treat diabetic macular edema, a retinal disease that can lead to blindness. The company called Iluvien its most advanced drug candidate.

Amyris Biotechnologies, Inc. to Raise up to $100 Million in IPO

Mon, 19 Apr 2010 12:00:00 AM GMT

Reuters -- Amyris Biotechnologies Inc filed with U.S. securities regulators on Friday to raise up to $100 million in an initial public offering of common stock.

Nycomed Still Plans IPO

Mon, 12 Apr 2010 12:00:00 AM GMT

ZURICHClosely held pharmaceutical company Nycomed SCA Monday said it still plans to launch an initial public offering despite a U.S. advisory panel voting not to recommend its lung drug Daxas.

Alimera Sciences Files for $87 Million IPO

Wed, 07 Apr 2010 12:00:00 AM GMT

Reuters -- Alimera Sciences Inc filed with U.S. regulators on Tuesday to raise up to $87 million in an initial public offering of common stock. The Alpharetta, Georgia-based biopharmaceutical firm expects to offer 6 million shares at a price range of $14 to $17 a share, the company said in a filing with the U.S Securities and Exchange Commission.

Anthera Pharmaceuticals, Inc. Seeks IPO for Company With No Sales as Offerings Slump

Mon, 22 Feb 2010 12:00:00 AM GMT

AB Science Preparing Paris IPO; 50 Million Euro IPO Seen Beginning of March

Wed, 03 Feb 2010 12:00:00 AM GMT

Ironwood Pharmaceuticals IPO Raises Less Than Expected-Says Underwriter

Wed, 03 Feb 2010 12:00:00 AM GMT

Med BioGene Files Registration Statement for Proposed $24.25M U.S. IPO

Wed, 30 Dec 2009 12:00:00 AM GMT

U.S. Biotech Codexis Pharmaceuticals Files for $100 Million IPO

Wed, 30 Dec 2009 12:00:00 AM GMT

Tengion Inc. Files $40.25 Million IPO

Mon, 28 Dec 2009 12:00:00 AM GMT

AVEO Pharmaceuticals, Inc. Files Registration Statement for Initial Public Offering

Thu, 17 Dec 2009 12:00:00 AM GMT

Ironwood Pharmaceuticals Files Registration Statement for Initial Public Offering

Mon, 23 Nov 2009 12:00:00 AM GMT

Trius Therapeutics Files for IPO

Mon, 09 Nov 2009 12:00:00 AM GMT

Alimera Sciences Re-Files for IPO

Mon, 02 Nov 2009 12:00:00 AM GMT

pehub.com -- Alimera Sciences Inc., an Atlanta-based ophthalmic pharmaceutical company, has filed for an $80 million IPO. This comes less than two months after Alimera withdrew registration for a $75 million IPO due to current public market conditions.

Talecris Biotherapeutics Raises $950 Million in Biggest Biopharma IPO in Three Years

Fri, 02 Oct 2009 12:00:00 AM GMT

Omeros Corporation Announces IPO of 6.8 Million Shares

Fri, 18 Sep 2009 12:00:00 AM GMT

Anthera Pharmaceuticals, Inc. Plans $70 Million IPO

Wed, 16 Sep 2009 12:00:00 AM GMT

Omeros Corporation Plans to Test Waters with First Washington IPO in Two Years, Sources Say

Thu, 27 Aug 2009 12:00:00 AM GMT

Cumberland Pharmaceuticals Raises $85 Million IPO, First Pharma IPO in Nearly Two Years

Wed, 12 Aug 2009 12:00:00 AM GMT

Mead Johnson Nutrition Company $720 Million IPO Breaks 12-week Drought

Wed, 11 Feb 2009 12:00:00 AM GMT

NEW YORK, Feb 10 (Reuters) - Mead Johnson Nutrition Co's initial public offering Tuesday raised $720 million, exceeding expectations and making it the largest IPO in nearly 10 months, but the deal won't necessarily mean a thaw in the U.S. IPO market.

Mead Johnson Nutrition Company Sets Terms for IPO, Targets Febuary Date

Thu, 29 Jan 2009 12:00:00 AM GMT

NEW YORK, Jan 28 (Reuters) - Mead Johnson Nutrition Co on Monday set the terms of its planned $562.5 million initial public offering, according to a regulatory filing.

Bristol-Myers Squibb Company Announces Filing of IPO Registration Statement of Its Wholly-owned Subsidiary

Tue, 16 Sep 2008 12:00:00 AM GMT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY - News) today announced that its wholly-owned subsidiary, Mead Johnson Nutrition Company, has filed a registration statement with the U.S. Securities and Exchange Commission for an initial public offering (IPO) of its Class A common stock.

In April 2008, Bristol-Myers Squibb Company announced it would file a registration...

Osmetech Plc Announces Initial Public Offering of American Depositary Shares

Fri, 12 Sep 2008 12:00:00 AM GMT

PASADENA, Calif.--(BUSINESS WIRE)--Osmetech plc, a molecular diagnostics company, (LSE:OMH - News) (proposed NASDAQ Global Market Symbol: OSMH) today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of 5,500,000 American Depositary Shares (ADSs) (representing 192,500,000 ordinary shares...

AutoGenomics Files Registration Statement for Initial Public Offering

Fri, 25 Jul 2008 12:00:00 AM GMT

CARLSBAD, Calif., July 25 /PRNewswire/ -- AutoGenomics, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. The number of shares of common stock to be offered, all of which are expected to be offered by AutoGenomics, Inc., and the price range for...

Pfizer Inc. Spun-Off Japan Lab, RaQualia Targets IPO by 2011

Thu, 03 Jul 2008 12:00:00 AM GMT

TOKYO, July 3 (Reuters) - RaQualia, a pharma venture that was recently spun off by drug maker Pfizer Inc (PFE.N: Quote, Profile, Research, Stock Buzz), aims to go public by the first quarter of 2011, its president said on Thursday.

Alimera Sciences Files for $75 Million IPO

Wed, 02 Jul 2008 12:00:00 AM GMT

WASHINGTON, July 1 (Reuters) - Biopharmaceutical company Alimera Sciences Inc on Tuesday filed to raise up to $75 million in an initial public offering of common stock.

Mexico Health Firm Genomma Shares Priced in IPO

Wed, 18 Jun 2008 12:00:00 AM GMT

MEXICO CITY, June 18 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. ("Genomma" or "the Company") today announced the pricing of its initial public offering. The offering consisted of 130,869,566 series B shares; 73.5% was placed with international investors and 26.5% was placed with Mexican investors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080618/MXW00...

Aldagen, Inc. Files for $80.5 Million IPO

Mon, 12 May 2008 12:00:00 AM GMT

WASHINGTON, May 9 (Reuters) - Biopharmaceutical company Aldagen Inc filed with regulators on Friday to raise up to $80.5 million in an initial public offering of common stock.

Epocrates Inc. Files for $75M IPO

Fri, 18 Apr 2008 12:00:00 AM GMT

WASHINGTON, April 17 (Reuters) - Epocrates Inc, a provider of clinical information and support tools to healthcare professionals, on Thursday filed with regulators to raise up to $75 million in an initial public offering.